Why use it

The IMDC risk group directly informs first-line treatment selection in mRCC. Favorable-risk patients achieve superior outcomes with TKI monotherapy (sunitinib, pazopanib) or IO/TKI combinations, while Intermediate- and Poor-risk patients derive the greatest benefit from IO-based combinations (nivolumab + ipilimumab or IO + TKI). The model is the primary stratification factor in all major phase III mRCC trials (CheckMate 214, KEYNOTE-426, CLEAR, CheckMate 9ER).

About

The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Risk Model — also known as the Heng criteria — is the most widely used prognostic stratification tool for patients with metastatic renal cell carcinoma (mRCC). Originally developed in 2009 by Daniel Heng and colleagues from a multicenter cohort of patients treated with VEGF-targeted therapy (sunitinib, sorafenib, or bevacizumab), the model identifies 6 adverse prognostic factors: poor performance status (KPS <80%), time from diagnosis to systemic treatment <1 year, anaemia (Hgb below normal), hypercalcaemia (corrected Ca above normal), neutrophilia (neutrophils above normal), and thrombocytosis (platelets above normal). Patients are classified as Favorable (0 factors), Intermediate (1–2 factors), or Poor (3–6 factors) risk. The model has been validated across multiple treatment eras including immunotherapy (nivolumab, ipilimumab, pembrolizumab) and IO/TKI combinations, and is incorporated into international guidelines (NCCN, ESMO, EAU) to guide first-line treatment selection.

When to use

All patients with newly diagnosed or progressive metastatic RCC before initiating first-line systemic therapy
Treatment selection between IO/IO (nivolumab + ipilimumab), IO/TKI combinations, or TKI monotherapy
Patient counseling and informed consent regarding expected outcomes and median survival
Clinical trial eligibility stratification and enrollment
Second-line and subsequent treatment planning after disease progression

Formula

IMDC Risk Factors (1 point each): 1. KPS <80% (poor performance status) 2. Time from diagnosis to treatment <1 year 3. Haemoglobin below lower limit of normal 4. Corrected calcium above upper limit of normal 5. Neutrophil count above upper limit of normal 6. Platelet count above upper limit of normal Risk Groups: Favorable: 0 factors — median OS ~43 months; 2-yr OS ~75% Intermediate: 1–2 factors — median OS ~23 months; 2-yr OS ~53% Poor: 3–6 factors — median OS ~8 months; 2-yr OS ~7%

Pearls & pitfalls

The IMDC model superseded the MSKCC (Motzer) criteria in the VEGF-targeted therapy era and is now the international standard for mRCC risk stratification.
KPS <80% (Karnofsky Performance Status) corresponds to ECOG ≥2 — patients who are not fully ambulatory and require assistance with self-care.
"Time from diagnosis to treatment <1 year" refers to the interval from initial RCC diagnosis to initiation of FIRST systemic therapy for metastatic disease — not prior nephrectomy.
Laboratory values are defined as below (for anaemia/hypocalcaemia) or above (for hypercalcaemia/neutrophilia/thrombocytosis) the institutional normal reference range — not absolute values.
The IMDC model was validated in the IO era (CheckMate 214, KEYNOTE-426) and remains prognostically valid across treatment regimens.
Poor-risk patients (3–6 factors) have very limited median survival (~8 months historically) — aggressive supportive care, early palliative care integration, and consideration of clinical trial enrollment are priorities.
Favorable-risk patients treated with IO/TKI combinations achieve 5-year OS rates exceeding 50% in recent trials — a dramatic improvement over historical outcomes.
The IMDC model does not include histological subtype — non-clear cell RCC (papillary, chromophobe, collecting duct) has different biology and treatment considerations beyond IMDC risk.

Next steps

Favorable Risk (0 factors): TKI monotherapy (sunitinib, pazopanib) or IO/TKI (pembrolizumab + axitinib, lenvatinib + pembrolizumab, nivolumab + cabozantinib) are all options. IO/IO (nivolumab + ipilimumab) shows inferior PFS in favorable risk. Discuss with patient. Intermediate/Poor Risk (1–6 factors): IO/IO (nivolumab + ipilimumab) — first-line preferred per CheckMate 214 for Int/Poor risk; OR IO/TKI combinations (pembrolizumab + axitinib, lenvatinib + pembrolizumab). TKI monotherapy is an alternative but generally inferior to IO-based regimens. All patients: MDT discussion, performance status optimization, bone-directed therapy (denosumab or zoledronic acid) if bone metastases present.

Evidence

Heng DY et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents. J Clin Oncol. 2009;27(34):5794-5799. PMID:19826129. Multicenter cohort n=645. Validated in: Heng DY et al. External validation and comparison with other models of the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model. Lancet Oncol. 2013;14(2):141-148. n=849 patients. Applied to IO era: Motzer RJ et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal Cell Carcinoma. N Engl J Med. 2018;378(14):1277-1290 (CheckMate 214).

References

Heng DY et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents. J Clin Oncol. 2009;27(34):5794-5799. — link
Heng DY et al. External validation and comparison with other models of the International Metastatic RCC Database Consortium prognostic model. Lancet Oncol. 2013;14(2):141-148. — link
Motzer RJ et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal Cell Carcinoma (CheckMate 214). N Engl J Med. 2018;378(14):1277-1290. — link
Rini BI et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal Cell Carcinoma (KEYNOTE-426). N Engl J Med. 2019;380(12):1116-1127. — link

IMDC Risk Model for Metastatic RCC

Calculator